Research Article

Assessment of HER2/neu among Female with Invasive Ductal Breast Carcinoma, Using Manual Tissue Microarray Technology in Khartoum State, Sudan

Rania M. Sidahmed
University of Gezira, Sudan
* Corresponding author
Abdalraheem A. Babiker
University of Gezira, Sudan
Elhadi A. Ahmed
University of Gezira, Sudan
Alaa E. Abbas
University of Gezira, Sudan
DOI icon 10.24018/ejbiomed.2022.1.4.20

Read Counter
338

Downloads
266

Citations

Share

Article Sidebar

Submitted 2022-07-19
Published 2022-08-31

Read counter = 338 times

Table of Contents

Article Main Content

The human epidermal growth factor receptor-2 (HER2), which is expressed in large amount in 20%-30% of breast cancer patients, is associated with disease recurrences, shortened disease survival, and bad prognosis. The aim of this study is to evaluate the expression of (Her2/neu) receptor as a diagnostic and prognostic marker in Invasive Ductal Breast cancer in Sudanese female patients. The study was performed on 35 archival paraffin blocks previously diagnosed as invasive ductal breast cancer (IDC), then a second diagnosis was done using IHC staining (Her2/neu). The obtained information is arranged in a standard master sheet, then analyzed using a statistical package for social science (SPSS) version 20 computer program. The age 30-45years was the most frequent age group 48.6% (17/35), followed by 46-60 years 40% (14/35). The majority of samples were grade III 74.3% (26/35) and the samples of grade II were 25.7% (9/35). the majority of TMA results were positive for Her2/neu receptor 65.7% (23/35) and the negative results were 34.3% (12/35) the majority of TMA score were (+) 31.4% (11/35), followed by (++) 17.2% (6/35), then (+++) 11.4% (4/35), then (++++) 5.7% (2/35), and the negative result were, 34.3% (12/35). There was a significant relation between H&E diagnosis with TMA result for Her2/ neu diagnosis that the P-value (0.0002). There was an insignificance relation between H&E diagnosis of grades with TMA results for Her2/ neu diagnosis that the P-value (0.08). In conclusion, HER2 is over-expressed in 65.7% of the patient while internationally it is over-expressed in 15-30%. This provides valuable prognostic and predictive implications in order to choose the suitable treatment for the patients.

Keywords: Breast cancer diagnosis; H&E; HER2/neu; Sudan

References

  1. Li N., Deng Y., Zhou L., Tian T., Yang S., Wu Y. et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017. Journal of hematology & oncology, 2019;12(1):1-12.
     Google Scholar
  2. Ji P., Gong Y., Jin M.-L., Hu X., Di G.-H. and Shao Z.-M. The burden and trends of breast cancer from 1990 to 2017 at the global, regional, and national levels: results from the global burden of disease study 2017. Frontiers in oncology, 2020;10:650.
     Google Scholar
  3. Saeed I. E., Weng H. Y., Mohamed K. H. and Mohammed S. I. Cancer incidence in Khartoum, Sudan: first results from the Cancer Registry, 2009–2010. Cancer medicine, 2014;3(4):1075-1084.
     Google Scholar
  4. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K. et al. Race, breast cancersubtypes, and survival in the carolina breast cancer study. JAMA, 2006;295:2492-2502.
     Google Scholar
  5. Simon R., Mirlacher M. and Sauter G. Tissue microarray (TMA). Biotechniques, 2018;36(1).
     Google Scholar
  6. Skaland I., Øvestad I., Janssen E. A. M., Klos J., Kjellevold K. H., Helliesen T., Baak J. P. A. Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer. J Clin Pathol, 2008;61:68–71. doi:10.1136/jcp.2007.046763.
     Google Scholar
  7. Gologan D., Leavitt M. O., Muşat S., Pleşea I. E., Raluca Stan L. G., Pleşea R. M., and Militaru M. Tissue microarrays – brief history, techniques and clinical future. Rom J Morphol Embryol, 2020 Oct-Dec; 61(4): 1077–1083.
     Google Scholar
  8. Sidahmed R. M., Algail A. M., Abuidris D. O., Mohammed A. A., Mohammed M. E. Optimization of the diagnosis of prostate cancer by application of immunohistochemistry in the Gezira State, Sudan. European academic research, 2016;III(10).
     Google Scholar
  9. Hamad A. M., SidAhmed R. M., Haj Mukhtar N. S., Alanazi H. G., Ahmed H. G. Status and association of BRCA1 and BRCA2 mutation with clinicopathological features in sudanese patients with breast cancer. European Journal of Biology and Biotechnology, 2022 DOI 10.24018/ejbio.2022.3.1.309.
     Google Scholar
  10. Babiker S., Nasir O., Marzogi A., Bogari M., Alghamdi T. Prospective Breast Cancer Risk Factors Prediction in Saudi Women. Saudi Journal of Biological Sciences, 2020;27(6):1624-163.
     Google Scholar
  11. Saleh H., Rageh T., Alhassanin S., Megahed,M. Upper limb lymphedema related to breast cancer therapy: incidence, risk factors, diagnostic techniques, risk reduction and optimal management. International Surgery Journal, 2018;5(11), 3633-3639.
     Google Scholar
  12. Juneja K., Varshney A., Kumar R., Singla M., Sharma P., Sharma V. K. BRCA1 expression and its association with histological typing, grade, ER, PR, HER2 in carcinoma of breast. Indian J Pathol Oncol, 2019;6(3), 376-80.
     Google Scholar
  13. Galvez M., Castaneda C. A., Sanchez J., Castillo M., Rebaza L. P., Calderon G., et al. Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy. World Journal of Clinical Oncology, 2018;9(2), 33–41.
     Google Scholar
  14. Sundquist M., Brudin L., Tejler G. Improved survival in metastatic breast cancer 1985-2016. Breast, 2017;31:46-50. doi: 10.1016/j.breast.2016.10.005.
     Google Scholar
  15. Cooke T., Reeves J., Lanigan A. & Stanton P. HER2 as a prognostic and predictive marker for breast cancer. Annals of Oncology, 2001;12 (Suppl. I): S23-S28).
     Google Scholar
  16. Sikandar B., Shafique Y., Bukhari U., Memon S. Expression of Hormone receptor and human epidermal growth factor receptor (HER2/neu) status of breast carcinoma and their correlation with clinico-pathological parameters. Biomed J Sci & Tech Res, 2020;25(2). BJSTR. MS.ID.004173.
     Google Scholar
  17. Yaqo R. T., Keorges G. J., Alnaqshabandi Sarah M.M., Abdullah K. M. Evaluation of HER2/Neu gene in equivocal cases assessed by IHC in invasive breast cancer. AVFT, 2021;40(6), ISSN 2610-7988.
     Google Scholar
  18. Ramieri M. T., Murari R., Botti C., Pica E., Zotti G. and Luigi Alo P. Detection of HER2 Amplification Using the SISH Technique in Breast, Colon, Prostate, Lung and Ovarian Carcinoma. Anticancer Research, 2010; 30: 1287-1292.
     Google Scholar
  19. Skaland I., Øvestad I., Janssen E. A. M., Klos J., Kjellevold K. H., Helliesen T., Baak J. P. A. Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer. J Clin Pathol: first published as 10.1136/jcp.2007.0467 3 on 5 April 2007.
     Google Scholar
  20. Keshgegian A. A. and Cnaan A. erbB-2 oncoprotein expression in breast carcinoma: poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody. American Journal of Clinical Pathology, 1997;108(4):456–463.
     Google Scholar
  21. Hoang M. P., Sahin A. A., Ordo`nez N. G., and Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. American Journal of Clinical Pathology, 2000;113(6):852–859.
     Google Scholar
  22. Press M. F., Hung G., Godolphin W., and Slamon D. J. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Research, 1994;54(10):2771–2777.
     Google Scholar
  23. Penault-Llorca F., Adelaide J., Houvenaeghel G., Hassoun J., Birnbaum D., and Jacquemier J. Optimization of immuno- histochemical detection of ERBB 2 in human breast cancer: impact of fixation. Journal of Pathology, 1994;173(1):65–75.
     Google Scholar
  24. Jacobs T. W., Gown A. M., Yaziji H., Barnes M. J., and Schnitt S. J. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry: a study of interlabo- ratory agreement. American Journal of Clinical Pathology, 2000;113(2):251–258.
     Google Scholar
  25. Thuan Dang Cong, Tung Nguyen Thanh, Quynh Anh Nguyen Phan1, Ai Phuong Hoang Thi, Bao Song Nguyen Tran, Quoc Huy Nguyen Vu. Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross-Sectional Study in Vietnam. Asian Pac J Cancer Prev, 2020. DOI:10.31557/APJCP.2020.21.4.1135.
     Google Scholar